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A B S T R A C T
Objective. Transplant coronary artery disease (TCAD) is the limiting factor to long-term cardiac allograft survival;
however, presymptomatic diagnosis remains challenging. To that concern, we evaluated the association of abnormal
catheter-derived filling pressures with TCAD in pediatric heart transplant (HTx) recipients.
Design, Patients, Outcome Measures. Data from 52 presymptomatic pediatric HTx patients were analyzed.
Catheter-derived right ventricular end-diastolic pressure (RVEDP) and pulmonary capillary wedge pressure
(PCWP) were recorded. Biopsies were collected to verify the absence of rejection.
Results. TCAD was diagnosed an average of 8.3 years post-HTx in 20 (38%) patients, six of whom died and four
of whom underwent retransplantation. Catheter-derived pressure measurements showed that RVEDP was elevated
in TCAD compared with non-TCAD patients (9.5  6.0 vs. 5.4  4.7; P = .005), as was the PCWP (12.9  5.7 vs.
9.1  5.7; P = .012). Results from logistic regression analysis showed RVEDP > 10 mm Hg or PCWP > 12 mm Hg
was associated with TCAD (OR = 5.2; P = .010).
Conclusions. In this series, elevated ventricular filling pressures measured during routine surveillance catheteriza-
tions were associated with angiographic TCAD. Recognizing the association between elevated RVEDP/PCWP and
TCAD may prompt earlier diagnosis and treatment of this potentially lethal process.
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Introduction
Heart transplantation (HTx) is standardtherapy for end-stage pediatric heart failure
with a conditional survival of 50% at 13 years.1,2
The primary factor currently limiting longer-term
graft survival is transplant coronary artery disease
(TCAD) characterized by progressive coronary
luminal obliteration, which in part represents an
immune host response to newly recognized or
upregulated antigens expressed on donor endothe-
lial cells.
With the exception of a few recently developed
immunosuppressive agents which may slow but
likely not reverse this indolent process, retrans-
plantation is the only option for these patients.
Because TCAD mortality is high,3 timely diag-
nosis is critical. An estimated 31% of all deaths
occurring more than 1 year posttransplantation
are related to TCAD.4
Conventional diagnosis is based on selective
coronary angiography, which is neither adequately
sensitive nor specific. This modality generally fails
to detect luminal narrowing of diffuse, smaller
myocardial branches, and identifies only signifi-
cantly obstructive lesions as progression of the
disease effects anatomically larger epicardial ves-
sels.5,6 Intravascular ultrasound (IVUS) is the only
diagnostic strategy which has been shown to accu-
rately predict extent and progression of disease,
but IVUS is invasive and has inherent risks, par-
ticularly in children, and thus not routinely used in
posttransplant surveillance procedures.5 Several
other modalities remain largely investigational,
including dobutamine stress echocardiography,6,7
coronary flow reserve measurement by Doppler
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flow wire8 or contrast echocardiography,9 and
nuclear perfusion scans.10
Our recent anecdotal experience suggests that
patients with significant and progressive TCAD
appear to have elevated ventricular filling pres-
sures measured during routine catheterizations for
posttransplant biopsy and surveillance coronary
angiography, suggestive of diastolic dysfunction.
To date, there have been few investigations eva-
luating these hemodynamic measures with the
angiographic presence of TCAD in presymptom-
atic patients.11 The purpose of this study was to
evaluate the association of abnormal catheter-
derived filling pressures with TCAD in pediatric
HTx recipients.
Methods
This retrospective study was approved by the
Institutional Review Board (IRB) and was Health
Insurance Portability and Accountability Act
(HIPAA) compliant.
Patient Demographics
Data from catheterizations performed between
1990 and 2008 were reviewed for all patients
transplanted after 1990. Demographic data in-
cluding current age, age at HTx, and follow-up
time was recorded.
Institutional Norms
For the early part of the study period, (1990–2000)
coronary angiography was generally performed
for the clinical indication of unexplained ventricu-
lar dysfunction without rejection on endomyocar-
dial biopsy. For the later part of the study period,
(2001–2008) HTx patients without known TCAD
routinely underwent coronary angiography every
2 years. All patients reported in this series under-
went coronary angiography at least once.
Catheterization Data
Selective angiograms from all patients who under-
went surveillance coronary angiography were
reviewed, and patients were categorized into two
groups based on the presence or absence of angio-
graphic TCAD. Using standard techniques, four
to five endomyocardial biopsy specimens were
collected, placed in formalin, and sent to a cardiac
pathologist for grading to exclude concurrent
treatable rejection.
Recorded data from the catheterization mea-
surements included: right and left ventricular
end-diastolic pressures (using pulmonary capillary
wedge pressure [PCWP] as a surrogate for left
ventricular end-diastolic pressure [LVEDP] in
the absence of mitral valve disease), mean pulmo-
nary artery pressure, and presence or absence of
TCAD. Selective coronary angiograms were
reviewed independently by two physicians (RJG
and DCC) experienced in the interpretation of
TCAD angiograms. Abnormal vessels identified
by angiography were then identified according to
the Stanford grading scale.12
Statistical Analysis
Demographic data were expressed as mean with
standard deviation or median with range. Patients
were analyzed in two groups: (1) those with vs.
without TCAD, and (2) those who were retrans-
planted or died vs. those who were alive without
retransplantation. Catheterization-derived pres-
sures were compared between groups using the
two-tailed t-test, applying the Satterthwaite
method in the case of unequal variances. Logistic
regression analysis was conducted to evaluate mea-
sures potentially associated with TCAD and
death/retransplantation in univariate analysis. Sta-
tistical significance was defined as a P-value  .05.
Results
We identified 62 HTx who had coronary angiog-
raphy performed between 1990 and 2008. Hemo-
dynamic data were unavailable for six HTx
patients. Of the remaining 56 recipients, 53 were
considered eligible for the study. Hemodynamic
data obtained in the presence of cellular rejection
above grade 2R were excluded in three patients,
including one patient whose only catheterization
showed both TCAD and rejection. The patients’
median age at initial transplant was 6.8 years.
The overall survival for the cohort was 77% at a
median of 6.8 years after initial heart transplant. A
total of seven patients (13%) underwent retrans-
plantation, five because of documented TCAD
and two because of rejection without documented
TCAD.
Transplant coronary artery disease was diag-
nosed in 20 of 52 patients (38%). At the time of
TCAD diagnosis, 13 (65%) had one affected
vessel, four (20%) had two affected vessels, and
three (15%) had three affected vessels. All patients
with TCAD had left coronary disease and 30%
had right coronary disease as well. Eighteen
patients (90%) had Stanford B lesions, while eight
(40%) had type A lesions, and only two (10%) had
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type C lesions. Nearly 20% of catheterizations
within 2 years of transplant showed TCAD;
beyond this point, there was a steady increase with
time (Figure 1).
To compare the two groups of patients, we used
data from the time of TCAD diagnosis, or the
most recent data for those without TCAD
(Table 1). Patients with TCAD were older at
transplant (10.1 vs. 6.9 years, P = .05) and further
out from transplant (8.3 vs. 4.9 years, P = .0003).
Mean right ventricular end-diastolic pressure
(RVEDP) was 9.4 mm Hg in patients with TCAD
vs. 5.4 in patients without TCAD (P = .008,
Figure 2). Mean PCWP was 12.9 mm Hg in
patients with TCAD vs. 9.1 mm Hg in patients
without TCAD (P = .023, Figure 2). The asso-
ciation between high RVEDP (>10 mm Hg) or
PCWP (>12 mm Hg) and concurrent TCAD was
modeled using logistic regression. The odds of
TCAD were 5.2 times higher in patients with
elevations in one or both filling pressures (95%
confidence interval [CI]: 1.4–19.0; P = .010), com-
pared with patients with no elevations. Adjusting
for age at transplant did not result in a substantive
change in this odds ratio. Adjusting for time since
transplant, this odds ratio increased to 6.0 (95%
CI: 1.3–26.8; P = .020). The odds of TCAD
were 1.4 times higher with each year post-
transplant (95% CI: 1.1–1.8; P = .003). Mean
pulmonary artery pressures did not differ sub-
stantively between the groups (18.9 mm Hg vs.
16.5 mm Hg, P = .180).
Patients were also divided into those who sub-
sequently died or were retransplanted (D/R), vs.
those who were still alive and not retransplanted
(A/NR; Table 2). For this analysis, the most recent
Figure 1. Number of routine catheterizations performed on
post-heart transplant patients which showed coronary vas-
culopathy vs. time. Patients were censored at the time of
diagnosis of TCAD. TCAD, transplant coronary artery
disease.
Figure 2. Mean RVEDP and PCWP for patients without and
with coronary vasculopathy. Differences in both RVEDP and
PCWP were statistically significant (P = .008 and P = .023,
respectively). Error bars indicate standard deviation. TCAD,
transplant coronary artery disease; RVEDP, right ventricular
end-diastolic pressure; PCWP, pulmonary capillary wedge
pressure; LVEDP, left ventricular end-diastolic pressure;
mm Hg, millimeters of mercury.
Table 1. Hemodynamic data for patients without and with coronary vasculopathy
Overall Non-TCAD TCAD
Pn Mean (SD) N Mean (SD) n Mean (SD)
Patient age at transplant (y) 52 8.1 (5.7) 32 6.9 (5.5) 20 10.1 (5.5) .053
Time since transplant (y) 52 6.2 (3.5) 32 4.9 (2.8) 20 8.3 (3.5) <.001
RVEDP (mm Hg) 51 7.0 (5.6) 31 5.4 (4.7) 20 9.5 (6.0) .008
PCWP (mm Hg) 52 10.6 (5.9) 32 9.1 (5.7) 20 12.9 (5.7) .023
Mean PAP (mm Hg) 48 17.4 (6.0) 31 16.5 (5.7) 17 18.9 (6.3) .180
EF (%) 43 63.9 (10.6) 27 64.2 (9.9) 16 63.3 (12.1) .803
Overall study population is shown in the left column. Differences were statistically significant for time since transplant, RVEDP, and PCWP. TCAD, transplant
coronary artery disease; RVEDP, right ventricular end-diastolic pressure; PCWP, pulmonary capillary wedge pressure; PAP, pulmonary artery pressure; mm Hg,
millimeters of mercury; SD, standard deviation; EF, left ventricular ejection fraction.
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complete set of hemodynamic measurements,
prior to retransplantation if applicable, was used.
Mean RVEDP was 10.4 mm Hg in D/R patients,
vs. 5.1 in A/NR patients (P = .015, Figure 3). Mean
PCWP was 13.7 mm Hg in D/R patients, vs.
9.1 mm Hg in A/NR patients (P = .037, Figure 3).
Results from logistic regression showed a 4.0
increased odds of subsequent death or retransplant
for patients with elevated RVEDP and/or PCWP
(95% CI: 1.1–14.3; P = .032), compared with
patients without such elevations. There were no
statistical differences between groups in age or
time since transplant.
Discussion
These data suggest that right and left ventricular
diastolic pressures are elevated at the time of
TCAD diagnosis. This is important because,
despite the presence of established criteria,12
angiographic diagnosis of TCAD remains highly
variable and operator-dependent. Conversely,
RVEDP and PCWP can be measured quite accu-
rately in nearly any patient with venous access, and
their measurement adds little extra time to a right
heart catheterization done for endomyocardial
biopsy.
Our data are consistent with findings from Law
and colleagues, who conducted a retrospective
study of 18 TCAD patients with matched controls,
finding mean RVEDP and PCWP of 11 mm Hg
and 14 mm Hg, respectively, in TCAD patients,
vs. 6 mm Hg and 8 mm Hg in transplanted non-
TCAD matched controls.11 Our study includes a
larger group of patients followed over a longer
period of time, and suggests that these hemody-
namic generalizations seem to apply to retrans-
planted patients as well.
Our reported incidence of TCAD is higher
than the general incidence reported in registry
data.13 However, the patients included in this study
are significantly older, and our data agree with
those previously reported for older age groups. In
addition, because of evolving practices and immu-
nosuppressive regimens over the relatively long
follow-up period, we would caution readers from
using this series to determine the overall incidence
of TCAD.
Recent evidence indicates that remodeling
events leading to concentric hypertrophy are
initiated as early as 1 week after heart transplan-
tation. In addition, those patients with early con-
centric hypertrophy develop TCAD at a faster rate
and have poorer graft survival.14 Right and left
ventricular filling pressures are markers of dias-
tolic function and increase with increasing degrees
of hypertrophy. Given this, it is not surprising
that an association between TCAD, RVEDP, and
PCWP would be observed. Published studies
involving prediction of PCWP in adult patients
Table 2. Hemodynamic data for patients who were alive and not retransplanted vs. those who died or been retransplanted
Alive/no re-HTx Died/re-HTx
Pn Mean (SD) n Mean (SD)
Patient age at transplant (y) 36 7.8 (5.8) 16 9.0 (5.6) 0.476
Time since transplant (y) 36 6.5 (3.5) 16 6.4 (4.0) 0.933
RVEDP (mm Hg) 35 5.1 (2.7) 16 10.4 (7.7) 0.015
PCWP (mm Hg) 36 9.1 (3.9) 16 13.7 (7.7) 0.037
Mean PAP (mm Hg) 34 16.9 (4.9) 14 19.0 (8.8) 0.416
EF (%) 32 65.6 (7.0) 11 60.3 (15.1) 0.285
Differences were statistically significant only for RVEDP and PCWP. HTx, heart transplant; RVEDP, right ventricular end-diastolic pressure; PCWP, pulmonary
capillary wedge pressure; PAP, pulmonary artery pressure; mm Hg, millimeters of mercury; SD, standard deviation; EF, left ventricular ejection fraction.
Figure 3. Mean RVEDP and PCWP for patients who were
alive and not retransplanted (A/N) at last follow-up vs.
patients who had died or been retransplanted (D/R).
Differences in both RVEDP and PCWP were statistically
significant (P = .015 and P = .037, respectively). Error
bars indicate standard deviation. RVEDP, right ventricular
end-diastolic pressure; PCWP, pulmonary capillary wedge
pressure; LVEDP = left ventricular end-diastolic pressure;
mm Hg, millimeters of mercury.
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typically cite a PCWP of 15 mm Hg or higher
as a significant elevation; pressures below this
are considered normal.15 In the current study,
we found that filling pressures of greater than
10–12 mm Hg were significant and were associ-
ated with TCAD in the pediatric heart transplant
patients.
Early diagnosis remains a major challenge in
combating TCAD and promoting graft longe-
vity. In addition to their antirejection regimen,
nearly all patients are already treated with a com-
bination of agents designed to control hyper-
lipidemia, hyperglycemia, and hypertension.
Most studies have demonstrated some correlation
between hyperlipidemia and TCAD;16 however,
it is less clear whether hyperglycemia and
hypertension are independent risk factors for
TCAD.17 The availability of agents such as siro-
limus, which is known to slow the progression
of TCAD in adult patients14,18 and results in
prolonged survival in these patients,19 potentially
provides a specific anti-TCAD pharmacologic
therapy. Although prospective data in pediatric
patients are lacking, it is possible that unfavor-
able changes in right and left ventricular end-
diastolic pressures may guide the earlier use of
this agent.
The chief limitation of this study is its retro-
spective nature, resulting in less than complete
uniformity in data, especially early in the case
series. As with all venous pressures, RVEDP and
PCWP do vary with patients’ volume status, and
accurate hemodynamic tracings can be difficult to
obtain in anxious or undersedated patients. Other
limitations include the relatively small number of
patients with complete hemodynamic data both
before and after TCAD diagnosis, as well as opera-
tor dependence in coronary angiographic imaging
and interpretation.
Conclusions
Right and left ventricular filling pressures are sig-
nificantly elevated at the time of the diagnosis of
transplant coronary artery disease. These eleva-
tions are associated with mortality and the need
for retransplantation. Further study is necessary to
determine if early pharmacologic intervention,
based on these hemodynamic data, results in
improved outcome in this population.
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